IL-17RA Antagonist Therapy for Anti-TNF-alpha Resistant Psoriasis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Patients with psoriasis who do not respond to or cannot tolerate anti-TNF-alpha antibodies require alternative therapeutic options to manage their condition effectively.
Innovation Solution
Administration of an IL-17RA antagonist, specifically a monoclonal antibody targeting IL-17RA, which blocks the biological activities of IL-17A, IL-17F, IL-17A/F, and IL-25, offering a novel mechanism to inhibit inflammation and clinical symptoms in psoriasis patients who are ineffective or intolerant to anti-TNF-alpha antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If anti-TNF-alpha antibody therapy is used to treat psoriasis, then inflammatory symptoms are suppressed, but treatment effectiveness is insufficient for non-responders and intolerant patients
Solution Approach 1:
The patent changes the therapeutic parameter from anti-TNF-alpha mechanism to anti-IL-17RA mechanism. By targeting a different cytokine pathway (IL-17RA instead of TNF-alpha), the treatment achieves effectiveness in patients who do not respond to or cannot tolerate anti-TNF-alpha therapy, thus resolving the contradiction between treatment reliability and patient population adaptability
Solution Approach 2:
The patent introduces an alternative therapeutic mediator (IL-17RA antagonist) to replace the ineffective or intolerable mediator (anti-TNF-alpha antibody). This intermediary approach provides a different biological pathway to achieve the same therapeutic goal of suppressing psoriasis inflammation, thereby expanding treatment options for non-responders and intolerant patients
2Adaptability or versatility
If alternative therapy options are provided for anti-TNF-alpha non-responders, then treatment coverage is expanded, but therapeutic mechanism complexity increases
Solution Approach 1:
The patent segments the psoriasis treatment population into different response categories (anti-TNF-alpha responders vs. non-responders/intolerant patients) and provides targeted therapy for each segment. By dividing the patient population and applying mechanism-appropriate treatments, the patent expands treatment coverage while managing complexity through structured patient stratification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The IL-17RA antagonist significantly reduces psoriasis severity, as measured by clinical global impression and Psoriasis Area and Severity Index scores, providing an effective treatment option for patients who do not respond to or cannot tolerate anti-TNF-alpha antibodies, such as adalimumab, infliximab, certolizumab pegol, and golimumab.
Implementation Method 1
AM-14 is a human CHO cell-derived IgG2 monoclonal antibody that binds to human IL-17RA and blocks the biological activities of IL-17A, IL-17F, IL-17A/F heterodimer, and IL-25
Data Source
Figure 1(A)~1(C)
Figure 2(D)~2(E)
Figure 3
AI summary
The present invention relates to a therapeutic agent for pustular psoriasis or psoriatic erythroderma that is administered to a psoriasis patient that has been administered with an anti-TNF-alpha antibody, comprising an IL-17RA antagonist as an active ingredient; and to a therapeutic agent for psoriasis that is administered to a psoriasis patient that cannot be treated with an anti-TNF-alpha antibody, comprising an IL-17RA antagonist as an active ingredient. In addition, the present invention also relates to a method for the treatment of pustular psoriasis or psoriatic erythroderma, comprising administering an IL-17RA antagonist to a psoriasis patient that has been administered with an anti-TNF-alpha antibody; and to a method for the treatment of psoriasis, comprising administering an IL-17RA antagonist to a psoriasis patient that cannot be treated with an anti-TNF-alpha antibody.